Research Tracker›Biomarker Atlas›Lyme Disease›CCL19

CCL19 in Lyme Disease

CCL19, also described as CC chemokine ligand 19, belongs to the inflammatory group of Lyme Disease (Lyme borreliosis, Borrelia burgdorferi infection) markers and is reported to be raised relative to healthy controls. Symptom domains tied to this marker in the source include lymphocyte trafficking — research. The evidence summarised here comes from Lantos et al. 2021 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedInflammatory

Summary

Direction in Lyme Disease↑ Elevated — higher than in the comparison group
CategoryInflammatory
Also described asCC chemokine ligand 19
Compared againstHC (healthy controls)
Associated symptomsLymphocyte trafficking — research
Test typeBlood test (serum / plasma / whole blood)
SourceLantos et al. 2021 — doi:10.1016/j.idc.2021.05.001
Condition atlasLyme Disease Biomarker Atlas

Related Inflammatory markers in Lyme Disease

Full list: Lyme Disease Biomarker Atlas.

Frequently asked questions

Is CCL19 high or low in Lyme Disease?

Elevated. Studies summarised in the OSMF atlas report higher CCL19 in Lyme Disease than in healthy controls. Source: Lantos et al. 2021.

What symptoms is CCL19 associated with in Lyme Disease?

The cited literature associates this marker with Lymphocyte trafficking — research. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures CCL19?

It is measured as a blood test (serum / plasma / whole blood). Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal CCL19 result diagnostic of Lyme Disease?

No. No single biomarker is diagnostic of Lyme Disease. CCL19 findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). CCL19 in Lyme Disease: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/lyme/ccl19.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from lyme.json · Browse: Lyme Disease atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.